Generic Times Product News

Pharmacy Times
Volume 0

Doxycycline Tablets

Marketed by: Ranbaxy Pharmaceuticals Inc (Princeton, NJ)

Compared to: Adoxa (Bioglan Pharmaceutical Co)

Indication: June 2, 2006?Ranbaxy Pharmaceuticals Inc received approval from the FDA to manufacture and market 50-, 75-, and 100-mg doxycycline tablets. The tablets are indicated as adjunctive therapy for a range of infections when caused by susceptible strains of microorganisms, including respiratory tract and urinary tract infections, skin and skin structure infections, and severe acne.

Dosage Form: Tablets: 50, 75, and 100 mg

For More Information:

Finasteride Tablets USP

Marketed by: Teva Pharmaceuticals (North Wales, Pa)

Compared to: Proscar (Merck & Co Inc)

Indication: June 19, 2006?Teva Pharmaceuticals announced the introduction and availability of finasteride tablets USP. Finasteride tablets are indicated for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate to improve symptoms and reduce the risk of the need for surgery, including transurethral resection of the prostate and prostatectomy.

Dosage Form: Tablets: 5 mg

For More Information: 888-TEVA-USA (888-838-2872)

Metronidazole Topical Gel 0.75%

Marketed by: Fougera, a division of ALTANA Inc (Melville, NY)

Compared to: MetroGel (Galderma)

Indication: June 6, 2006?Fougera announced that it was first to market with metronidazole topical gel USP 0.75%. The product was approved by the FDA and is indicated for the treatment of inflammatory papules and pustules of rosacea.

Dosage Form: Gel: 45-g tube

For More Information: 800-645-9833

Sronyx (Levonorgestrel and Ethinyl Estradiol Tablets USP 0.1 mg/0.02 mg)

Marketed by: Watson Pharmaceuticals Inc (Corona, Calif)

Compared to: Levlite (Berlex)

Indication: June 1, 2006?Watson Pharmaceuticals announced that the FDA granted final approval for its Abbreviated New Drug Application for levonorgestrel and ethinyl estradiol tablets USP, 0.1 mg/0.02 mg. These tablets are indicated for the prevention of pregnancy.

Dosage Form: Tablets: 0.1 mg levonorgestrel/0.02 mg ethinyl estradiol

For More Information:

Zonisamide Capsules

Marketed by: Ranbaxy Pharmaceuticals Inc (Princeton, NJ)

Compared to: Zonegran (Dainippon Pharmaceutical USA Corp)

Indication: June 9, 2006?Ranbaxy Pharmaceuticals announced plans to market zonisamide capsules in the United States through a strategic partnership with Invagen Pharmaceuticals Inc (Hauppauge, NY). Zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.

Dosage Form: Capsules: 25, 50, and 100 mg

For More Information:

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.